Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.34 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721053 | 0.80 | GSK3B (0.50) | MAPTSMN1; SMN2RAB9AKDM4EJUN | |
| SCHEMBL27823817 | 0.80 | MAPT (0.41) | MAPTL3MBTL1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL27832731 | 0.80 | MAPT (0.41) | MAPTL3MBTL1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL691592 | 0.78 | GSK3B (0.52) | JUNNFKB1NFKB2RELANAPRT | |
| SCHEMBL1877325 | 0.78 | NAPRT (0.60) | MAPTL3MBTL1SMN1; SMN2RAB9ANAPRT | |
| SCHEMBL30175321 | 0.78 | NAPRT (0.60) | MAPTL3MBTL1SMN1; SMN2RAB9ANAPRT | |
| SCHEMBL9192054 | 0.76 | KMT2A (0.46) | L3MBTL1SMN1; SMN2RAB9AKDM4ETDP1 | |
| SCHEMBL25660809 | 0.75 | MAPT (0.37) | MAPTL3MBTL1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL27717025 | 0.75 | BAZ2B (0.42) | MAPTL3MBTL1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL9198640 | 0.75 | PPARA (0.38) | MAPTL3MBTL1SMN1; SMN2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-2635560-B1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| CN-101558059-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-12-03 | — | — | CN | disclosed |
| CN-101528232-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-11-12 | — | — | CN | disclosed |
| CN-101998952-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2014-10-08 | — | — | CN | disclosed |
| CN-103958511-A | 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis | REDDYS LAB LTD DR | 2014-07-30 | — | — | CN | disclosed |
| CN-103827105-A | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors | REDDYS LAB LTD DR | 2014-05-28 | — | — | CN | disclosed |
| US-8673950-B2 | Dihydrooxazol-2-amine derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130345241-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20120108609-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-03 | — | — | US | disclosed |
| CN-102361859-A | Heteroaryl compounds useful as Raf kinase inhibitors | BIOGEN IDEC INC | 2012-02-22 | — | — | CN | disclosed |
| CN-101743242-A | Heterocyclic compounds useful as RAF kinase inhibitors | BIOGEN IDEC INC | 2010-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947206-B2 | cGAS antagonist compounds | CGAS, STING1, GLS2 | MAPT 4349/4885L3MBTL1 4572/4885SMN1; SMN2 3105/4885 |
| US-20120108609-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | TAAR1, TAAR5, HCRTR1 | MAPT 205/4885L3MBTL1 4348/4885SMN1; SMN2 2472/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | MAPT 2829/4885L3MBTL1 4587/4885SMN1; SMN2 354/4885 |
| US-20130345241-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | TAAR1, TAAR5, HCRTR1 | MAPT 204/4885L3MBTL1 4331/4885SMN1; SMN2 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.